Meridian Int Research

NuMom Post Partum Depression Study

A research study is evaluating an investigational drug, NORA520, to determine if it is safe and effective in treating adults with severe postpartum depression. Study participants who qualify and enroll in this study will be asked to participate for up to 60 days, composed of 1 screening visit, 3 night in-patient stay, and 2 follow-up visits. Participants will be randomly assigned (like the flip of a coin) to receive either the investigational drug NORA520 or a placebo.

STUDY CRITERIA

To participate in this study, participants*:

- Must be female ages 18-45 (inclusive)
- Must have been diagnosed with postpartum depression, with a depressive episode beginning between the 3rd trimester and 4th week postpartum
- Must have had a baby within the last 9 months

**Other eligibility criteria apply*. Participants receive investigational drug at no cost. Reimbursement for study-related time, travel, and childcare may be available.

For more information or to see if you are eligbile for participation, please visit:

Phone: 305 705-4494

www.meridianintlresearch.com

NORA520 is an investigational drug that is not approved by the Food and Drug Administration (FDA) or any other global health authority. Its safety and effectiveness have not been established.